Skip to main content
Journal cover image

The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.

Publication ,  Journal Article
Dart, RC; Bush, SP; Heard, K; Arnold, TC; Sutter, M; Campagne, D; Holstege, CP; Seifert, SA; Lo, JCY; Quan, D; Borron, S; Meurer, DA ...
Published in: Ann Emerg Med
September 2019

STUDY OBJECTIVE: The antivenom currently available for treatment of systemic black widow envenomation (latrodectism) is composed of equine whole immunoglobin. Although considered effective, it has been associated with anaphylaxis and 2 reported fatalities. We test the efficacy and safety of new equine antivenom composed of purified F(ab')2 antibody fragments. METHODS: A randomized, double-blind, placebo-controlled trial was conducted at 16 sites across the United States. Subjects aged 10 years or older with moderate to severe pain because of black widow spider envenomation received F(ab')2 antivenom or placebo. The primary outcome measure was treatment failure, which was defined as failure to achieve and maintain clinically significant reduction in pain for 48 hours posttreatment. Secondary measures of pain intensity differences and summed pain intensity difference were computed. Adverse events were recorded. RESULTS: Sixty patients were treated (29 antivenom and 31 placebo). The mean age was 39 years and 68% were male. There were 15 treatment failures in the antivenom group and 24 in the placebo group (P=.019). Differences in pain intensity difference between groups were lower at each postbaseline point, and the mean summed pain intensity difference was greater for the antivenom group (difference 2,133; 95% confidence interval 177 to 4,090). No deaths or serious drug-related adverse events were detected. CONCLUSION: The F(ab')2 antivenom met the predefined primary outcome of reduced treatment failures. Secondary outcomes of pain intensity difference and summed pain intensity difference also supported efficacy. The rate of symptom improvement in the placebo group was higher than expected, which may be related to enrollment criteria or placebo effect.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Emerg Med

DOI

EISSN

1097-6760

Publication Date

September 2019

Volume

74

Issue

3

Start / End Page

439 / 449

Location

United States

Related Subject Headings

  • Young Adult
  • Spider Venoms
  • Spider Bites
  • Pain Measurement
  • Pain
  • Middle Aged
  • Male
  • Immunologic Factors
  • Immunoglobulin Fab Fragments
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dart, R. C., Bush, S. P., Heard, K., Arnold, T. C., Sutter, M., Campagne, D., … Anderson, V. E. (2019). The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Ann Emerg Med, 74(3), 439–449. https://doi.org/10.1016/j.annemergmed.2019.02.007
Dart, Richard C., Sean P. Bush, Kennon Heard, Thomas C. Arnold, Mark Sutter, Danielle Campagne, Christopher P. Holstege, et al. “The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.Ann Emerg Med 74, no. 3 (September 2019): 439–49. https://doi.org/10.1016/j.annemergmed.2019.02.007.
Dart, Richard C., et al. “The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.Ann Emerg Med, vol. 74, no. 3, Sept. 2019, pp. 439–49. Pubmed, doi:10.1016/j.annemergmed.2019.02.007.
Dart RC, Bush SP, Heard K, Arnold TC, Sutter M, Campagne D, Holstege CP, Seifert SA, Lo JCY, Quan D, Borron S, Meurer DA, Burnham RI, McNally J, Garcia-Ubbelohde W, Anderson VE. The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Ann Emerg Med. 2019 Sep;74(3):439–449.
Journal cover image

Published In

Ann Emerg Med

DOI

EISSN

1097-6760

Publication Date

September 2019

Volume

74

Issue

3

Start / End Page

439 / 449

Location

United States

Related Subject Headings

  • Young Adult
  • Spider Venoms
  • Spider Bites
  • Pain Measurement
  • Pain
  • Middle Aged
  • Male
  • Immunologic Factors
  • Immunoglobulin Fab Fragments
  • Humans